Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis

NCT: NCT07885345 · NOT_YET_RECRUITING

NCT IDNCT07885345
StatusNOT_YET_RECRUITING
Start Date2026-10-07
Completion2027-12-31
SponsorUniversity of Erlangen-Nürnberg Medical School (OTHER)
First posted
Last updated

Brief Summary

This study investigates changes in the skin and joints of people with psoriasis (PsO) and psoriatic arthritis (PsA) using two non-invasive imaging methods called raster-scan optoacoustic mesoscopy (RSOM) and multispectral optoacoustic tomography (MSOT). The study will include 192 adults, including people with PsO, people with PsA, people at increased risk of developing these conditions, and healthy participants. RSOM will be used to examine small blood vessels and other features of the skin, while MSOT will be used to examine joints and tissue characteristics. In selected participants, a small skin sample will also be collected for laboratory analysis. The researchers will investigate relationships between the imaging findings, clinical characteristics, and laboratory findings from skin samples. Computer-based and artificial intelligence (AI)-supported methods will also be used to explore patterns across these different types of data. The aim is to improve the understanding of changes associated with PsO and PsA and to identify potential imaging features that could be investigated as biomarkers in future studies. The imaging and AI analyses performed in this study are for research purposes only and will not be used to make clinical diagnoses or treatment decisions.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑